Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2013 Sep 3;159(5):349-57. doi: 10.7326/0003-4819-159-5-201309030-00672.

PMID:
23798026
2.

Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention.

Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW.

Ann Intern Med. 2012 Dec 4;157(11):817-22.

PMID:
22910836
3.

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Coffin PO, Scott JD, Golden MR, Sullivan SD.

Clin Infect Dis. 2012 May;54(9):1259-71. doi: 10.1093/cid/cis011. Epub 2012 Mar 12.

4.

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.

5.

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD.

Ann Intern Med. 2012 Feb 21;156(4):271-8. doi: 10.7326/0003-4819-156-4-201202210-00004. Erratum in: Ann Intern Med. 2012 Jun 5;156(11):840.

PMID:
22351712
6.

Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.

Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD.

PLoS One. 2011;6(12):e26783. doi: 10.1371/journal.pone.0026783. Epub 2011 Dec 2.

7.

Economic model of a birth cohort screening program for hepatitis C virus.

McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC.

Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.

PMID:
22135116
8.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.

Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.

9.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

10.

Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.

Di Martino V, Crouzet J, Hillon P, Thévenot T, Minello A, Monnet E.

J Viral Hepat. 2011 Jul;18(7):493-505. doi: 10.1111/j.1365-2893.2011.01476.x. Epub 2011 May 27.

PMID:
21692956
11.

All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.

El-Kamary SS, Jhaveri R, Shardell MD.

Clin Infect Dis. 2011 Jul 15;53(2):150-7. doi: 10.1093/cid/cir306. Epub 2011 Jun 10.

12.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

13.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1. doi: 10.1016/j.cgh.2011.03.004. Epub 2011 Mar 11.

PMID:
21397729
14.

Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006.

Williams IT, Bell BP, Kuhnert W, Alter MJ.

Arch Intern Med. 2011 Feb 14;171(3):242-8. doi: 10.1001/archinternmed.2010.511.

PMID:
21325115
15.

Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.

Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, George J, Dore GJ.

J Hepatol. 2011 May;54(5):879-86. doi: 10.1016/j.jhep.2010.08.035. Epub 2010 Oct 23.

PMID:
21145812
16.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Jul;139(1):120-9.e18. doi: 10.1053/j.gastro.2010.04.013. Epub 2010 Apr 24.

PMID:
20399780
17.

Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.

Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V.

Value Health. 2010 Jun-Jul;13(4):479-86. doi: 10.1111/j.1524-4733.2009.00691.x. Epub 2010 Jan 21.

18.

Demographics of a large cohort of urban chronic hepatitis C patients.

Siddiqui FA, Ehrinpreis MN, Janisse J, Dhar R, May E, Mutchnick MG.

Hepatol Int. 2008 Sep;2(3):376-81. doi: 10.1007/s12072-008-9086-x. Epub 2008 Jul 25.

19.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team.

N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027.

20.

Diagnosis, management, and treatment of hepatitis C: an update.

Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases.

Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759. No abstract available.

PMID:
19330875

Supplemental Content

Support Center